• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » The Evidence Base for Polypharmacy in ADHD

The Evidence Base for Polypharmacy in ADHD

March 24, 2022
Pavan Madan, MD.
From The Carlat Child Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Pavan Madan, MD. Dr. Madan has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

REVIEW OF: Baker M et al, J Child Adolesc Psychopharmacol 2021;31(3):148–163


TYPE of Study: Literature review


Psychotropic polypharmacy is increasingly the norm in clinical practice. We use it to address persistent symptoms or to target comorbid conditions, though we do so at the risk of increased side effects, more drug interactions, and worsened patient compliance. This review examines the evidence base for polypharmacy in the treatment of ADHD in children and adolescents.


The authors’ literature search found 39 studies and 17 randomized controlled trials (RCTs), a “relatively limited evidence base … to support a practice that occurred in 20% of outpatient visits in 2007 and is likely higher today.”


Nearly all trials included a stimulant. The most common additions were alpha-agonists, followed by risperidone and atomoxetine.


Sixteen of the 37 studies combined a stimulant and an alpha-agonist. RCT data showed that for stimulant partial responders, the combination of stimulant and alpha-agonist was superior to alpha-agonist alone in reducing residual ADHD symptoms, and superior to stimulant alone if there was a history of partial response to stimulant monotherapy, with an effect size of about 0.4. Combination treatment was associated with bradycardia, sedation, somnolence, and hypotension.


For ADHD with comorbid aggression and disruptive behavior, RCT data found that stimulants alone had a large effect size. Combination treatment with divalproex or risperidone did improve response beyond stimulant monotherapy, with the greatest support for risperidone; however, there was a price to pay. Despite the short study durations and the low dosages of risperidone (<2 mg/day) in all the studies, significant prolactin elevations and weight gain were seen.


One RCT of atomoxetine found no evidence of improvement with added MPH, with the suggestion that “optimizing dose and allowing adequate duration for response is favorable to adding medications.”


For management of comorbid anxiety, depression, and disruptive mood dysregulation disorder, data from four RCTs of SSRIs with stimulants showed this very common combination, while safe, had minimal benefit for anxiety and mood comorbidities.


The authors conclude the data support existing guidelines to start with stimulant monotherapy for ADHD. Still, antipsychotics are worth considering, despite their side effects, when aggression is severe or persistent. The authors recommend using measurement-based care to determine if the benefit of an added medication is worth the risk.


CCPR’s Take: Combination treatment for ADHD may be beneficial, though it comes at the cost of more side effects. Adding an alpha-agonist is helpful in partial responders to stimulants, and, in line with clinical lore, adding risperidone can be helpful for aggression. Remember that side effects can differ based on pubertal ­status.

Child Psychiatry
KEYWORDS adhd aggression central-alpha-agonists combined-pharmacotherapy divalproex polypharmacy risperidone stimulants
Pavan Madan, MD.

Methylphenidate Improves Mood and Boredom in Children with ADHD

More from this author
www.thecarlatreport.com
Issue Date: March 24, 2022
SUBSCRIBE NOW
Table Of Contents
CME Post-Test - ADHD in Children and Adolescents, CCPR, April/May/June 2022
Note From the Editor-in-Chief
The Evidence Base for Polypharmacy in ADHD
Methylphenidate Improves Mood and Boredom in Children with ADHD
Talking with Parents About Stimulant Treatment
Treating Anxiety Disorders in Children: The New AACAP Clinical Practice Guideline
Practical Issues with Prescribing ADHD Meds
DOWNLOAD NOW
Featured Book
  • CMFB2e_Cover.png

    Child Medication Fact Book for Psychiatric Practice, Second Edition (2023)

    All the important facts covering child and adolescent psychopharmacology.
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • teen_depression.jpeg
    Child Psychiatry

    Assessment of Non-Suicidal Self-Injury in Children and Adolescents

    Learn how to assess and intervene with NSSI, including ideas for supporting autonomy while addressing the behavior.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.